Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

MrNickJones Jan. 21 at 12:13 AM

$ERNA added some here at 1.14 ah like the volume lets see if it hold PM

0 · Reply

JL_TradeZ Jan. 20 at 10:39 PM

EOD RECAP 20/01 $SEGG $SGN $ERNA $TWG $POLA

0 · Reply

Smithmark12 Jan. 20 at 10:10 PM

$ERNA Pump and dump

0 · Reply

Digitalization2026 Jan. 20 at 10:08 PM

$AKAN Setup 📡 Akanda Corp pivoted from legacy cannabis into telecom infrastructure via First Towers & Fiber in Mexico. FTF owns ~30 revenue-producing towers and 700+ km of fiber. Assets are real, but recurring revenue is still developing, which explains volatility. Valuation context 💡 At current prices, AKAN’s market cap is compressed compared to telecom infrastructure peers like $AMT and $CCI, which trade on proven lease income. If AKAN executes and monetizes assets, multi-dollar share prices become possible. What to watch 👀 • Overnight / premarket: filings or PR drops • Tomorrow: volume expansion, dip buyers • This week: tower leases, fiber monetization, financing updates Price targets 🎯 (speculative) $2–3 base | $5–8 momentum 🚀 | $10+ rerate 🔥 Bottom line ⚖️ Low price reflects risk and uncertainty, not zero value. Execution and volume decide the next move. $ERNA $IMTE

0 · Reply

JL_TradeZ Jan. 20 at 10:04 PM

$ERNA

1 · Reply

jamestocklover Jan. 20 at 9:59 PM

$AKAN $4 OPEN, THEN $10+ TOMORROW💥🚀💯 $IMTE 👀 $LVRO 👀 $IVF 👎 $ERNA 👀

1 · Reply

BearishAlgo Jan. 20 at 9:52 PM

$ERNA watching

0 · Reply

AlertsAndNews Jan. 20 at 9:45 PM

$ERNA quite the pop here.

0 · Reply

Ultra_Calls Jan. 20 at 9:42 PM

$ERNA IN HERE

0 · Reply

SuperGreenToday Jan. 10 at 3:14 AM

$ERNA

0 · Reply

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 6 weeks ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 3, 2025, 8:30 AM EST - 6 weeks ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2025, 8:50 AM EST - 7 weeks ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Nov 11, 2025, 7:00 AM EST - 2 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 10, 2025, 8:35 AM EST - 2 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 2 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Oct 29, 2025, 8:33 AM EDT - 2 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 3 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 10, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 4 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 8 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 10 months ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 11 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 2 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 3 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Feb 22, 2023, 8:00 AM EST - 3 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Jan 4, 2023, 8:30 AM EST - 3 years ago

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Dec 20, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

MrNickJones Jan. 21 at 12:13 AM

$ERNA added some here at 1.14 ah like the volume lets see if it hold PM

0 · Reply

JL_TradeZ Jan. 20 at 10:39 PM

EOD RECAP 20/01 $SEGG $SGN $ERNA $TWG $POLA

0 · Reply

Smithmark12 Jan. 20 at 10:10 PM

$ERNA Pump and dump

0 · Reply

Digitalization2026 Jan. 20 at 10:08 PM

0 · Reply

JL_TradeZ Jan. 20 at 10:04 PM

$ERNA

1 · Reply

jamestocklover Jan. 20 at 9:59 PM

$AKAN $4 OPEN, THEN $10+ TOMORROW💥🚀💯 $IMTE 👀 $LVRO 👀 $IVF 👎 $ERNA 👀

1 · Reply

BearishAlgo Jan. 20 at 9:52 PM

$ERNA watching

0 · Reply

AlertsAndNews Jan. 20 at 9:45 PM

$ERNA quite the pop here.

0 · Reply

Ultra_Calls Jan. 20 at 9:42 PM

$ERNA IN HERE

0 · Reply

SuperGreenToday Jan. 10 at 3:14 AM

$ERNA

0 · Reply

DARKP00L Jan. 6 at 1:54 PM

$ERNA 08:18 on Jan. 06 2026 Ernexa Therapeutics Completes Pre‑IND Meeting With FDA, Secures Pathway To IND And First‑In‑Human Ovarian Cancer Trial In H2 2026 #tradeideas

0 · Reply

Tusto Dec. 29 at 3:15 PM

$ERNA = a scam RS, diluting and change name is all these F@ckers do.

0 · Reply

DumbMoneyD Dec. 25 at 1:18 PM

$ERNA Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Commercial adoption must become steadier to neutralize skepticism around sustainability. If milestones arrive on time, perception can shift faster than fundamentals. The market will respond to evidence, not speculation.

0 · Reply